Cargando…
Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
OBJECTIVES: Chronic hyperlipidemia and hyperglycemia are characteristic features of type 2 diabetes (T2DM) that are thought to cause or contribute to β-cell dysfunction by “glucolipotoxicity.” Previously we have shown that acute treatment of pancreatic islets with fatty acids (FA) decreases acetylch...
Autores principales: | Doliba, Nicolai M., Liu, Qin, Li, Changhong, Chen, Pan, Liu, Chengyang, Naji, Ali, Matschinsky, Franz M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641685/ https://www.ncbi.nlm.nih.gov/pubmed/29031723 http://dx.doi.org/10.1016/j.molmet.2017.07.017 |
Ejemplares similares
-
Accumulation of 3-hydroxytetradecenoic acid: Cause or corollary of glucolipotoxic impairment of pancreatic β-cell bioenergetics?
por: Doliba, Nicolai M., et al.
Publicado: (2015) -
Glucokinase Activators for Diabetes Therapy: May 2010 status report
por: Matschinsky, Franz M., et al.
Publicado: (2011) -
Control of Insulin Secretion by Cholinergic Signaling in the Human Pancreatic Islet
por: Molina, Judith, et al.
Publicado: (2014) -
α Cell dysfunction in islets from nondiabetic, glutamic acid decarboxylase autoantibody–positive individuals
por: Doliba, Nicolai M., et al.
Publicado: (2022) -
Alterations of Pancreatic Islet Structure, Metabolism and Gene Expression in Diet-Induced Obese C57BL/6J Mice
por: Roat, Regan, et al.
Publicado: (2014)